|
1
|
Zhang S, Wang X, Gupta A, Fang X, Wang L
and Zhang C: Expression of IL-17 with tumor budding as a prognostic
marker in oral squamous cell carcinoma. Am J Transl Res.
11:1876–1883. 2019.PubMed/NCBI
|
|
2
|
Wu K, Jiang Y, Zhou W, Zhang B, Li Y, Xie
F, Zhang J, Wang X, Yan M, Xu Q, et al: Long noncoding RNA RC3H2
facilitates cell proliferation and invasion by targeting
MicroRNA-101-3p/EZH2 Axis in OSCC. Mol Ther Nucleic Acids.
20:97–110. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen L, Zhang S, Wu J, Cui J, Zhong L,
Zeng L and Ge S: circRNA_100290 plays a role in oral cancer by
functioning as a sponge of the miR-29 family. Oncogene.
36:4551–4561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao Z, Gao D, Ma T and Zhang L:
MicroRNA-141 suppresses growth and metastatic potential of head and
neck squamous cell carcinoma. Aging (Albany NY). 11:921–932. 2019.
View Article : Google Scholar
|
|
5
|
Wang Y, Guo W, Li Z, Wu Y, Jing C, Ren Y,
Zhao M, Kong L, Zhang C, Dong J, et al: Role of the EZH2/miR-200
axis in STAT3-mediated OSCC invasion. Int J Oncol. 52:1149–1164.
2018.PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flynt AS and Lai EC: Biological principles
of microRNA-mediated regulation: Shared themes amid diversity. Nat
Rev Genet. 9:831–842. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Li Y, Hou D, Shi Q, Yang S and Li
Q: MicroRNA-375 inhibits growth and enhances radiosensitivity in
oral squamous cell carcinoma by targeting insulin like growth
factor 1 receptor. Cell Physiol Biochem. 42:2105–2117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang K, Jin J, Ma T and Zhai H: MiR-139-5p
inhibits the tumorigenesis and progression of oral squamous
carcinoma cells by targeting HOXA9. J Cell Mol Med. 21:3730–3740.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fu S, Chen HH, Cheng P, Zhang CB and Wu Y:
MiR-155 regulates oral squamous cell carcinoma Tca8113 cell
proliferation, cycle, and apoptosis via regulating p27Kip1. Eur Rev
Med Pharmacol Sci. 21:937–944. 2017.PubMed/NCBI
|
|
11
|
Yu EH, Tu HF, Wu CH, Yang CC and Chang KW:
MicroRNA-21 promotes perineural invasion and impacts survival in
patients with oral carcinoma. J Chin Med Assoc. 80:383–388. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu Y, Tang Z, Jiang B, Chen J and Fu Z:
MiR-198 functions as a tumor suppressor in breast cancer by
targeting CUB domain-containing protein 1. Oncol Lett.
13:1753–1760. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Zhao H, Xin Y and Fan L:
MicroRNA-198 inhibits proliferation and induces apoptosis of lung
cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995.
2014. View Article : Google Scholar
|
|
14
|
Tan S, Li R, Ding K, Lobie PE and Zhu T:
MiR-198 inhibits migration and invasion of hepatocellular carcinoma
cells by targeting the HGF/c-MET pathway. FEBS Lett. 585:2229–2234.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui Z, Zheng X and Kong D: Decreased
miR-198 expression and its prognostic significance in human gastric
cancer. World J Surg Oncol. 14:332016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto K, Kawaguchi M, Shimomura T,
Izumi A, Konari K, Honda A, Lin CY, Johnson MD, Yamashita Y,
Fukushima T and Kataoka H: Hepatocyte growth factor activator
inhibitor type-2 (HAI-2)/SPINT2 contributes to invasive growth of
oral squamous cell carcinoma cells. Oncotarget. 9:11691–11706.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Q, Wu T, Chen X, Li H, Du Z, Hao Y,
Peng J, Tai S, Song M and Cheng B: The poor outcome of second
primary oral squamous cell carcinoma is attributed to Bmi1
upregulation. Cancer Med. 7:1056–1069. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Zhong F, Chen H, Han L, Jin Y and Wang W:
Curcumin attenuates lipopolysaccharide-induced renal inflammation.
Biol Pharm Bull. 34:226–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang M, Wang J, Kong X, Chen H, Wang Y,
Qin M, Lin Y, Chen H, Xu J, Hong J, et al: MiR-198 represses tumor
growth and metastasis in colorectal cancer by targeting fucosyl
transferase 8. Sci Rep. 4:61452014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng CM, Shiah SG, Huang CC, Hsiao JR and
Chang JY: Up-regulation of miR-455-5p by the TGF-β-SMAD signalling
axis promotes the proliferation of oral squamous cancer cells by
targeting UBE2B. J Pathol. 240:38–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang KW, Kao SY, Wu YH, Tsai MM, Tu HF,
Liu CJ, Lui MT and Lin SC: Passenger strand miRNA miR-31* regulates
the phenotypes of oral cancer cells by targeting RhoA. Oral Oncol.
49:27–33. 2013. View Article : Google Scholar
|
|
23
|
Liang L, Feng L and Wei B: MicroRNA-1297
involves in the progression of oral squamous cell carcinoma through
PTEN. Saudi J Biol Sci. 25:923–927. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagai H, Hasegawa S, Uchida F, Terabe T,
Ishibashi Kanno N, Kato K, Yamagata K, Sakai S, Kawashiri S, Sato
H, et al: MicroRNA-205-5p suppresses the invasiveness of oral
squamous cell carcinoma by inhibiting TIMP-2 expression. Int J
Oncol. 52:841–850. 2018.PubMed/NCBI
|
|
25
|
Adel M, Kao HK, Hsu CL, Huang JJ, Lee LY,
Huang Y, Browne T, Tsang NM, Chang YL and Chang KP: Evaluation of
lymphatic and vascular invasion in relation to clinicopathological
factors and treatment outcome in oral cavity squamous cell
carcinoma. Medicine (Baltimore). 94:e15102015. View Article : Google Scholar
|
|
26
|
Mattiotti A, Prakash S, Barnett P and van
den Hoff MJB: Follistatin-like 1 in development and human diseases.
Cell Mol Life Sci. 75:2339–2354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao C, Huang X, Gong Y and Lin Q:
Discovery of core genes in colorectal cancer by weighted gene
co-expression network analysis. Oncol Lett. 18:3137–3149.
2019.PubMed/NCBI
|
|
28
|
Shi Y, Fang N, Li Y, Guo Z, Jiang W, He Y,
Ma Z and Chen Y: Circular RNA LPAR3 sponges microRNA-198 to
facilitate esophageal cancer migration, invasion, and metastasis.
Cancer Sci. 111:2824–2836. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye L, Li S, Ye D, Yang D, Yue F, Guo Y,
Chen X, Chen F, Zhang J and Song X: Livin expression may be
regulated by miR-198 in human prostate cancer cell lines. Eur J
Cancer. 49:734–740. 2013. View Article : Google Scholar
|
|
30
|
Wang J, Dan G, Shangguan T, Hao H, Tang R,
Peng K, Zhao J, Sun H and Zou Z: MiR-198 represses the
proliferation of HaCaT cells by targeting cyclin D2. Int J Mol Sci.
16:17018–17028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ray J, Hoey C, Huang X, Jeon J, Taeb S,
Downes MR, Boutros PC and Liu SK: MicroRNA-198 suppresses prostate
tumorigenesis by targeting MIB1. Oncol Rep. 42:1047–1056.
2019.PubMed/NCBI
|
|
32
|
Wood DJ and Endicott JA: Structural
insights into the functional diversity of the CDK-cyclin family.
Open Biol. 8:1801122018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamilton E and Infante JR: Targeting
CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao X, Leone GW and Wang H: Cyclin
D-CDK4/6 functions in cancer. Adv Cancer Res. 148:147–169. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sheppard KE and AbuHammad S: CDK4/6
inhibition in cancer: The cell cycle splicing connection. Mol Cell
Oncol. 6:e16736432019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng H, Ge F, Du L, Zhang Z and Liu D:
MiR-34b-3p represses cell proliferation, cell cycle progression and
cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting
CDK4. J Cell Mol Med. 23:5282–5291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lang B and Zhao S: MiR-486 functions as a
tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.
Oncol Rep. 39:71–80. 2018.
|
|
38
|
Tarasewicz E, Hamdan R, Straehla J, Hardy
A, Nunez O, Zelivianski S, Dokic D and Jeruss JS: CDK4 inhibition
and doxorubicin mediate breast cancer cell apoptosis through Smad3
and survivin. Cancer Biol Ther. 15:1301–1311. 2014. View Article : Google Scholar : PubMed/NCBI
|
